Pfizer

Third Quarter 2022

Earnings Highlights

$22.6B
Revenue
-2% Op Decline
+2% Op Growth[1] excl. Paxlovid and Comirnaty[2]

$1.51
Rep. Dil. EPS
+6% Growth

$1.78
Adj. Dil. EPS[3]
+44% Op Growth

FY 2022 Guidance[4]
$99.5B–$102.0B
Revenue
Adj. Dil. EPS[3] $6.40–$6.50

$2.7B
Rep. R&D Expenses
+2% Op Growth

$8.7B
Returned to Shareholders Through Sept. 2022
$6.7B Cash Dividends
$2.0B Share Repurchases

"I continue to be proud of our colleagues' excellence, ingenuity and unwavering commitment to bringing breakthroughs to patients. Over the next 18 months, we expect to have up to 19 new products or indications in the market – including the five for which we have already begun co-promotion or commercialization earlier this year. Many of these 19 programs are already largely de-risked from a clinical perspective, the majority were discovered in-house, and nearly all would be for indications outside of COVID-19. If approved, we expect each of these to be key contributors to our growth aspirations through 2025 and beyond."



Albert Bourla
Chairman and Chief Executive Officer

Key Growth Drivers[5]

Primary Care | Specialty Care | Oncology

- **PAXLOVID™** COVID-19 Oral Treatment — $7,514M Revenue
- **COMIRNATY®** (COVID-19 Vaccine, mRNA) — $4,402M Revenue, -65% Op Decline, +83% U.S. Growth
- **Prevnar Family** — $1,607M Revenue[6], +14% Op Growth, +28% U.S. Growth
- **Eliquis®** (apixaban) tablets — $1,464M Revenue, +15% Op Growth, +33% U.S. Growth
- **Vyndamax®** (tafamidis) — $602M Revenue[7], +29% Op Growth, +44% U.S. Growth

Pipeline Spotlights[8]

- **Pfizer-BioNTech COVID-19 Vaccine, Bivalent** — U.S. emergency use authorization of Omicron BA.4/BA.5 bivalent booster dose granted for individuals 5+
- **Prevnar 20™** Pneumococcal 20-valent Conjugate Vaccine — Positive Phase 3 topline results for prevention of invasive pneumococcal disease in infants
- **TALZENNA®** talazoparib 1mg capsules — Positive Phase 3 topline results in combination with Xtandi in metastatic castration-resistant prostate cancer (mCRPC)
- Candidate **Pentavalent Meningococcal Vaccine** — Positive Phase 3 topline results for protection against meningococcal disease in adolescents and young adults
- Candidate **RSVpreF Vaccine** — Positive Phase 3 topline results for respiratory syncytial virus (RSV) prevention in adults 60+
- Candidate **Ritlecitinib** — Regulatory submissions completed in U.S., Europe, UK, China and Japan for oral treatment of alopecia areata
- Completed Acquisition **GBT** — Completed acquisition of biopharmaceutical company focused on sickle cell disease (SCD) treatments
- Completed Acquisition **biohaven** pharmaceuticals — Completed acquisition of Biohaven and its portfolio of calcitonin gene-related peptide (CGRP) assets for migraine

In September 2022, Pfizer announced an agreement to supply up to
6M
treatment courses
of Paxlovid to Global Fund as part of its COVID-19 Response Mechanism

Fortifying Long-Term Growth Plans

Business Development Opportunities
Goal to add at least $25B of risk-adjusted revenues to 2030 top-line expectations

COVID-19 Franchises
Expect to remain multi-billion dollar revenue generators

Potential Upcoming Launches[9]
Up to 19 potential launches expected over next 18-months

- Vaccines: 5
- Biosimilars: 1
- Oncology: 4
- Inflammation & Immunology: 3
- Internal Medicines: 1
- Launched: 5

What's Next

Anticipates projected revenue CAGR of at least 6% and double-digit adjusted diluted EPS[3] growth through 2025[10]

- **Maintain** patient centricity
- **Scale** emerging tech platforms
- **Invest** in areas we can win
- **Foster** a culture of innovation
- **Reduce** approval development cycle times

25 BY 2025 — Ambition of up to 25 breakthrough launches in patients' hands by 2025

Pfizer

investors.pfizer.com

Please reference Pfizer's Q3 2022 earnings release and SEC filings for additional information.

1 Operational growth. Reference to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates.

2 As used in this document, "Comirnaty" refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), the Comirnaty Original/Omicron BA.1 Vaccine, and Comirnaty Original/Omicron BA.4/BA.5 Vaccine. Comirnaty includes direct sales and alliance revenues related to sales of the above mentioned vaccines, which are recorded within Pfizer's Primary Care therapeutic area. It does not include revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the Pfizer CentreOne contract development and manufacturing organization.

3 Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and reported EPS attributable to Pfizer Inc. common shareholders—diluted before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. See the accompanying reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the third quarter and the first nine months of 2022 and 2021 of Pfizer's earning release furnished with Pfizer's Current Report on Form 8-K dated November 1, 2022. Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. See the Non- GAAP Financial Measure: Adjusted Income sections of Management's Discussion and Analysis of Financial Condition and Results of Operations in Pfizer's 2021 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarterly period ended July 3, 2022 and the accompanying Non- GAAP Financial Measure: Adjusted Income section of Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated November 1, 2022 for additional information.

4 Total company guidance. Please see Pfizer's Q3 2022 earnings release for additional details and assumptions regarding Pfizer's 2022 financial guidance.

5 Q3 financial performance.

6 Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult).

7 Presented figures include sales of both Vyndaqel and Vyndamax.

8 Pipeline updates as of October 31, 2022.

9 Reference the full set of materials in the Q3 2022 Earnings Presentation for certain information regarding potential product launches. Over the next 18 months, we expect to have up to 19 new products or indications in the market—including the five for which we have already begun co-promotion or commercialization earlier this year. All dates are preliminary, subject to change, and subject to clinical trial and regulatory success and availability of supply.

10 Projected revenue CAGR calculated from 2020–2025. Excludes the impact of Comirnaty and the COVID-19 oral treatment (Paxlovid), as well as recent or subsequent business development activities.

This document includes forward-looking statements about, among other things, Pfizer's anticipated operating and financial performance, product pipeline, in-line products and product candidates, product launches, revenue contributions, business plans, strategy and prospects, business development activities, manufacturing and product supply, capital allocation objectives, dividends and share repurchases that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to Pfizer's Annual Report on Form 10-K for the year ended December 31, 2021, and Pfizer's subsequent reports on Form 10-Q, including the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results," as well as Pfizer's subsequent reports on Form 8-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this document. These reports are available on Pfizer's website at www.pfizer.com and on the U.S. Securities and Exchange Commission's website at www. sec.gov. The forward-looking statements in this document speak only as of the original date of this document, and we undertake no obligation to update or revise any of these statements.